Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00439465 · OUTCOME

Number of Participants With Increased Expression of DAP10 and NKG2D on the CD8 Cell Population

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma · Source last updated 2019-03-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Pre-transplant and following the third and fourth cellular infusions

What was measured

* Isolate CD3+CD8+ and CD8+CD56+ from patients' blood following transplant. * Identify NKG2D and DAP10 expression. * Determine the mechanism of tumor cell killing and the relationship to NKG2D or DAP 10 expression. After isolating CD8+ cells from patient's blood samples using the AutoMACS, we will evaluate the expression of NKG2D and DAP10 on all CD8+ cells (CD3+CD8+ and CD8+CD56+cells) pre-transplant (Baseline) and following the third and fourth cellular infusions using phenotypic analysis. We postulate the increased expression of both DAP10 and NKG2D on the CD8 population immediately following APSCT and effector cell infusions when compared to baseline.

Analysis population: Sixteen out of nineteen participants samples were analyzed. Three participants' samples were not available for analysis.

Groups in this outcome

Ex-vivo Expanded Effector Cells

Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT) Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ex-vivo Expanded Effector Cells16

Reported measurements

Increased abs. NKG2D+CD3+CD8 Tcells
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ex-vivo Expanded Effector Cells12Not reportedNot reportedNot reportedNot reported
Increased abs. NKG2D+CD3-CD56+ T cells
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ex-vivo Expanded Effector Cells12Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        12
    title
    Increased abs. NKG2D+CD3+CD8 Tcells
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        12
    title
    Increased abs. NKG2D+CD3-CD56+ T cells
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
* Isolate CD3+CD8+ and CD8+CD56+ from patients' blood following transplant. * Identify NKG2D and DAP10 expression. * Determine the mechanism of tumor cell killing and the relationship to NKG2D or DAP 10 expression. After isolating CD8+ cells from patient's blood samples using the AutoMACS, we will evaluate the expression of NKG2D and DAP10 on all CD8+ cells (CD3+CD8+ and CD8+CD56+cells) pre-transplant (Baseline) and following the third and fourth cellular infusions using phenotypic analysis. We postulate the increased expression of both DAP10 and NKG2D on the CD8 population immediately following APSCT and effector cell infusions when compared to baseline.
groups
  1. description
    Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT) Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
    id
    OG000
    title
    Ex-vivo Expanded Effector Cells
param Type
COUNT_OF_PARTICIPANTS
population Description
Sixteen out of nineteen participants samples were analyzed. Three participants' samples were not available for analysis.
reporting Status
POSTED
time Frame
Pre-transplant and following the third and fourth cellular infusions
title
Number of Participants With Increased Expression of DAP10 and NKG2D on the CD8 Cell Population
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice